Torsdag 18 September | 10:46:23 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-13 08:30 Bokslutskommuniké 2025
2025-11-05 07:30 Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-15 - X-dag ordinarie utdelning SENZA 0.00 SEK
2025-05-14 - Årsstämma
2025-05-14 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning SENZA 0.00 SEK
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2022-05-05 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2021-05-05 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-11 - X-dag ordinarie utdelning SENZA 0.00 SEK
2020-05-08 - Årsstämma
2020-02-13 - Bokslutskommuniké 2019
2019-12-18 - Extra Bolagsstämma 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2019-05-15 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-09 - X-dag ordinarie utdelning SENZA 0.00 SEK
2018-05-08 - Årsstämma
2018-02-14 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Senzagen är verksamt inom medicinteknik. Bolaget utvecklar och genomför genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte testas på djur utan istället i provrör. Bolaget har utvecklat en teknologisk plattform som används för att studera substansers påverkan producerat av aktörer inom läkemedel, kosmetika- och kemikalieindustrin. Verksamheten bedrivs från huvudkontoret i Lund.
2025-09-18 08:00:00

SenzaGen is pleased to invite investors and media to its Capital Markets Day on Monday, 10 November 2025, at Sveavägen 20 (9th floor) in Stockholm. Presentations will be available live on site and via webcast.

The event will provide an in-depth overview of SenzaGen’s strategic priorities and value-creating initiatives that are driving the company towards profitable growth in non-animal testing. The upcoming strategic period, in turn, lays the foundation for the subsequent phase of the growth journey, enabling scalable and profitable expansion into new markets and product segments – something we will also touch upon during the day.

Presentations will be given by SenzaGen’s CEO Peter Nählstedt, together with members of the management team and other experts. All sessions will be held in English, with opportunities for participants to engage both in person and digitally.

A light lunch will be served from 11:30, followed by presentations from 12:15 to approximately 14:30, and concluding with networking over drinks and light refreshments.

Please register your attendance by 31 October 2025 via the following link: https://forms.office.com/r/9hnFrZ4ZiL

Please note that on-site seats are limited, and attendance will only be confirmed upon receipt of a confirmation email. The full agenda and additional event details will be published on SenzaGen’s website closer to the date and sent digitally to registered participants. Following the event, both the presentation materials and the recording will be accessible on SenzaGen’s website.